The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30, 2017:
38 negotiations are currently underway with 9 new files added since the last update of March 31, 2017:
Cosentyx (secukinumab): Use to treat psoriatic arthritis
Cosentyx (secukinumab): Used to treat ... Read More
16
May2017
03
May2017
PDCI Market Access is delighted to announce the addition of John-Paul Dowson to the PDCI team as an external Advisor and Strategic Partner. John-Paul is Managing Director of Roubaix Strategies Inc., an advisory firm dedicated to helping organizations evaluate, develop and implement highly effective private and public market access strategies, ... Read More
02
May2017
Join PDCI at 3rd Annual Canadian Institute Pharma Symposium
PDCI Market Access is delighted to participate in the 3rd Annual Canadian Institute’s Pharma Symposium. The Pharma Symposium brings together leading stakeholders in pharmaceutical market access & policy to analyze the key issues facing the industry in today’s complex environment. Participants will ... Read More
19
Apr2017
The new PMPRB Meds Entry Watch annual publication explores the market entry dynamics of new drugs launched in Canada and other international markets. This first edition of the report provides both a retrospective analysis of the new drugs launched over a six-year period from 2009 to 2014, and an early ... Read More
19
Apr2017
The drug products being evaluated as part of the October 2017 update to the List of Medications now been made public by INESSS. Health professionals, citizens, patients, and their associations and groups may submit comments on any of the products under consideration before May 12, 2017. As part of this ... Read More
13
Apr2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of March 31, 2017:
30 negotiations are currently underway with 3 new files added since the last update of February 28, 2017:
Votrient (pazopanib hydrochloride): Used to treat genitourinary metastatic renal cell carcinoma
Campral ... Read More
28
Mar2017
The updated guidelines recognize the substantial advances that have been made in the methods of economic evaluation and they offer up-to-date guidance on the best practices for determining the economic value of health technologies.
Available for download at the following link.
17
Mar2017
New CADTH Processes
Expanding CADTH’s Drug Review Processes to Include Radiopharmaceuticals
In collaboration with the participating jurisdictions, CADTH is pleased to announce that they will accept submissions for Radiopharmaceutical Submissions and Other Process Alignment Implementations effective April 1, 2017. Applicants/Submitters planning to file a submission or resubmission for a radiopharmaceutical on ... Read More
16
Mar2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of February 28, 2017:
33 negotiations are currently underway with 2 new files added since the last update of January 31, 2017:
Eylea (aflibercept): Used to treat macular edema secondary to branch retinal vein ... Read More
15
Mar2017
CADTH is hosting an online or in person event on Tuesday, March 28, 2017 to release the fourth edition of the Guidelines for the Economic Evaluation of Health Technologies: Canada.
The Guidelines are intended to help produce credible and standardized economic information that is relevant and useful to decision-makers in Canada’s ... Read More